Trial reportBMC infectious diseases2025
Parasite clearance of two commonly administered artemisinin-based combination therapies in under-five children with uncomplicated malaria in a comprehensive healthcare facility in South-Western Nigeria: a randomised controlled trial.
Trial report in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Population pharmacokinetics of lumefantrine in pregnant and non-pregnant Nigerian women receiving efavirenz-based antiretroviral therapy.European journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis research work aimed to study the parasite clearance of two commonly prescribed artemisinin-based combination therapies (ACTs) in under-five children with uncomplicated malaria in a comprehensive healthcare facility in Southwestern Nigeria.
methodsAn open-label, randomised controlled clinical trial was conducted. The participants were randomised into two treatment groups using simple randomisation by computer-generated random numbers. Children between the ages of six and 59 months with uncomplicated malaria in a comprehensive healthcare facility in southwestern Nigeria were enrolled after fulfilling the study criteria between July 2020 and December 2020. They had either artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine phosphate (DHAPQ) for three days. The participants were monitored for 42 days by examining blood films for malaria parasite density on days 1, 2, 3, 7, 14, 21, 28, 35, and 42. Malaria parasite genotyping by polymerase chain reaction (PCR) was done to differentiate between reinfection and recrudescence. The main outcome measures were malaria parasite clearance, adequate clinical and parasitological response on days 28 and 42 (ACPR28 and ACPR42), and tolerability.
resultsA total of 122 participants were randomised to receive either AL (61 participants) or DHAPQ (61) with a mean age of 23.6 ± 13.0 (months) and 27.6 ± 16.6 (months), respectively. Day 42 per protocol analysis included 113 participants – 57 in the AL group and 56 in the DHAPQ group after excluding the nine that were lost to follow-up. Although not statistically significant, the median baseline malaria parasite density of participants in AL group was higher than that in the DHAPQ group (3,600.0 parasite/µL, lower quartile (LQ) 2,420 parasite/µL, upper quartile (UQ) 5,399 parasite/µL versus 3,440.0 parasite/µL, LQ 2,640 parasite/µL, UQ 5,597 parasite/µL; p = 0.636). The mean fever clearance time was significantly lower in the AL group compared to the DHAPQ group (46.16 ± 3.31 h vs. 48.83 ± 8.95 h; p = 0.032). Parasite clearance time was shorter in the AL treatment group compared to DHAPQ (61.30 ± 23.75 h vs. 63.97 ± 23.42 h; p = 0.541), but this difference was not statistically significant. The day 42 PCR uncorrected cure rate in the AL group and DHAPQ group was 94.7% and 92.9% respectively (p = 0.679). The cure rate increased to 100% in both groups after PCR correction. Five participants in the DHAPQ group reported mild adverse events compared to none of those in the AL group.
conclusionThe study concluded that both DHAPQ and AL had good parasite clearance.
trial registrationRegistered on 10/07/2020 with the Pan African Clinical Trials Registry, Cochrane South Africa (PACTR202007553348930).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.